Ageing - Drug Pipeline Landscape, 2023

Ageing - Drug Pipeline Landscape, 2023

Ageing is the process during which structural and functional changes occur in an organism as a result of the passage of time. The changes manifest as a decline from the organism's peak fertility and physiological functions until death.

Smoking exposes skin to oxidative stress causing dryness, wrinkles, and other signs of premature aging. Tanning beds and exposure to the sun penetrate your skin with UV rays. These rays damage the DNA in skin cells, causing wrinkles. There are some very rare genetic conditions that can cause to show signs of aging in childhood and early puberty.

Signs and symptoms of aging include increased susceptibility to infection, decrease in height as the bones of our spines get thinner and lose some height, joint changes, stooped posture, slowed and limited movement, decrease in overall energy, constipation and urinary incontinence. Ageing can also be prevented with screening tests and immunizations.

Early aging, treatments that use retinoids, vitamin C, and alpha hydroxy acids may be enough. Chemical peels, dermabrasion, microneedling, ultrasound energy devices, or laser resurfacing may be an option for moderate to severe facial sun damage.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Ageing treatment such as Longeveron Mesenchymal Stem Cells, Rapamycin, Allogeneic Human Mesenchymal Stem Cells and others. Key players involved in the development of therapies to treat Ageing are AgelessRx, Galapagos NV, Longeveron Inc, RepliCel Life Sciences Inc and others. Three drugs are under clinical-stage Phase II clinical trials and two drugs are in Phase I clinical trials of development.

In October 2022, AgelessRx partnered with Longevity Labs on a descriptive study that has shown positive results for quality-of-life outcomes.

Report Highlights

Global Insight Service's, Ageing - Drug Pipeline Landscape, 2023 report provides an overview of the Ageing pipeline drugs. This report covers detailed insights on Ageing drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Ageing pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.